These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38650941)

  • 1. Editorial: Harnessing tumor microenvironment for gynecologic cancer therapy.
    Zhou L; Yi M
    Front Immunol; 2024; 15():1407128. PubMed ID: 38650941
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor associated macrophages in gynecologic cancers.
    Krishnan V; Schaar B; Tallapragada S; Dorigo O
    Gynecol Oncol; 2018 Apr; 149(1):205-213. PubMed ID: 29395307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-oncology for Gynecologic Malignancies.
    How J; Patel A; Jazaeri A
    Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and Opportunities for Immunotherapies in Gynecologic Cancers.
    Lee JM; Ivy SP; Kohn EC
    Oncology (Williston Park); 2016 Jan; 30(1):67-9. PubMed ID: 26791847
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immunotherapy in gynecologic oncology].
    Mallmann P
    Geburtshilfe Frauenheilkd; 1994 Nov; 54(11):M137-9. PubMed ID: 8719014
    [No Abstract]   [Full Text] [Related]  

  • 6. Current status of cancer immunotherapy for gynecologic malignancies.
    Nishio H; Iwata T; Aoki D
    Jpn J Clin Oncol; 2021 Feb; 51(2):167-172. PubMed ID: 33244581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Practical value of immunotherapy in gynecologic oncology].
    Mallmann P
    Zentralbl Gynakol; 1999; 121(4):183-4. PubMed ID: 10355094
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunotherapy in gynecologic oncology].
    Krebs D
    Zentralbl Gynakol; 1996; 118(10):578. PubMed ID: 8999715
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
    Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
    Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in Gynecologic Cancers: Are We There Yet?
    Pakish JB; Jazaeri AA
    Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
    Lee L; Matulonis U
    Gynecol Oncol; 2019 Jul; 154(1):236-245. PubMed ID: 30995960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of immunotherapy with thymopentin on the parameters of cellular immunity and the clinical course of gynecologic tumor patients].
    Mallmann P; Krebs D
    Onkologie; 1989 Jun; 12 Suppl 3():15-21. PubMed ID: 2532730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
    Jazaeri A; Coleman RL; Sood AK; Frumovitz MM; Soliman PT; Shafer A; Cutrera JJ; Klinger M; Sharafi SE; Johnson CAL; Villanueva VF; Hinchcliff EM; Dickens A; Cain KE; Anderson JE; Lu KH; Westin SN
    Gynecol Oncol; 2018 Nov; 151(2):374-380. PubMed ID: 30213435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies.
    Bourla AB; Zamarin D
    Oncology (Williston Park); 2016 Jan; 30(1):59-66, 69. PubMed ID: 26791846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell target antigens across major gynecologic cancers.
    Rodriguez-Garcia A; Minutolo NG; Robinson JM; Powell DJ
    Gynecol Oncol; 2017 Jun; 145(3):426-435. PubMed ID: 28377094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed.
    Levinson K; Dorigo O; Rubin K; Moore K
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e126-e140. PubMed ID: 31099679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on immune checkpoint inhibitors in gynecological cancers.
    Heong V; Ngoi N; Tan DS
    J Gynecol Oncol; 2017 Mar; 28(2):e20. PubMed ID: 28028993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Problems in association with basic research and biologic therapy of gynecologic malignancies].
    Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2003 Aug; 38(8):493-6. PubMed ID: 14627039
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: Novel immune markers and predictive models for immunotherapy and prognosis in breast and gynecological cancers.
    Wang F; Huang Q; Guo S; Traverso A; Teng F; Liu C
    Front Immunol; 2024; 15():1431245. PubMed ID: 38868773
    [No Abstract]   [Full Text] [Related]  

  • 20. Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities.
    Xu Y; Jiang J; Wang Y; Wang W; Li H; Lai W; Zhou Z; Zhu W; Xiang Z; Wang Z; Zhu Z; Yu L; Huang X; Zheng H; Wu S
    Front Immunol; 2021; 12():725330. PubMed ID: 34386017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.